Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Clinical trial NCT07281664 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07281664
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-01
- Primary completion
- 2028-12-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.